139. Back to Basics - Early HER2 Breast Cance...

We're back, baby! Michael and Josh predicted their ESMO journey would have eons to run, and they weren't wrong! For our first episode back in 2026, we revisit the important coverage of ESMO 2025, highlighting advances in upper gastrointestinal tract and hepatobiliary cancers. Thi ...  Show more

This week, we discuss neuroendocrine tumours and melanoma as our ESMO 25 journey continues. Trials for neuroendocrine cancers include HIF-2 alpha inhibitors, targeted alpha therapy, and a classic anti-PD-1/TIGIT bispecific antibody combined with standard etoposide and cisplatin c ...  Show more

In this episode, Dr. Jessica Steier and Dr. Sarah Scheinman discuss the complexities of cancer with Dr. Joe Zundell, a cancer biologist. They explore the definition of cancer, its prevalence, and the hallmarks that characterize cancer cells. The conversation delves into the mecha ...  Show more

What really causes cancer? Will we ever find a cure? And why does our mistrust of medicine and obsession with big pharma conspiracies have such a grip on the way we think about it? In this episode, Jonathan Van Ness sits down with oncologist Dr. Stacy Wentworth to explore the big ...  Show more

<div>Join us as we review recent practice-changing articles on the effect of combination statin and ezetimibe in reducing myalgias, male partner treatment for BV, semaglutide for MASH/liver fibrosis, exercise and cancer risk, and cytisinicline for smoking cessation. Fill your bra ...  Show more

We have another guest joining us this week! Dr. Allison Schepers, PharmD, BCOP is a Clinical Pharmacist Specialist at the Rogel Cancer Center at the University of Michigan where she focuses on GI, GU, and Thoracic malignancies! In this episode, Allison discusses the high yield ...